NO20032531L - Tetralon-derivater som antitumormidler - Google Patents
Tetralon-derivater som antitumormidlerInfo
- Publication number
- NO20032531L NO20032531L NO20032531A NO20032531A NO20032531L NO 20032531 L NO20032531 L NO 20032531L NO 20032531 A NO20032531 A NO 20032531A NO 20032531 A NO20032531 A NO 20032531A NO 20032531 L NO20032531 L NO 20032531L
- Authority
- NO
- Norway
- Prior art keywords
- alkyl
- amino
- hydrogen
- compounds
- alkylene chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D295/116—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings with the doubly bound oxygen or sulfur atoms directly attached to a carbocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Forbindelser med formel (1) hvor RI, R,2, R3, R4, R5, X og Y har betydningene angitt nedenfor, fremgangsmåte for fremstilling av disse forbindelser og farmasøytiske midler inneholdende en slik forbindelse har HDAC-inhibitoraktivitet. RI er valgt fra hydrogen, (1-4)alkyl, COOH, COO(l-4C)alkyl, R2, R3, R4, R5 uavhengig er valgt fra hydrogen, et halogenatom, en 1 -4C)alkyl-, trifluormetyl-, hydroksy-, (1 -4C)alkoksy-. aryloksy-, arylalkyloksy-, nitro-, amino-, (l-4C)alkylamino-, di[(l-4C)alkyl]-amino-, piperidino, morfolino, pyrrolidino, (1 -4C)alkanoylamino- eller en arylgruppe eller en heteroarylgruppe, eller henholdsvis R2 og R3 sammen eller R3 og R4 sammen eller R4 og R5 sammen kan danne en (1 -3C)alkylendioksyring, eller henholdsvis R2 og R3 sammen eller R3 og R4 sammen eller R4 og R5 sammen kan danne en (3-5C)alkylenkjede. Y er CH-CH-. X er en alkylenkjede med 4 til 10 karbonatomer som kan være mettet eller umettet med én eller to dobbeltbtndinger eller én eller to trippelbindinger eller én dobbelt- og én trippelbinding, og som kan være forgrenet eller rettkjedet eller avbrutt med en (3-7C)- cykloalkylring;
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00126820 | 2000-12-07 | ||
PCT/EP2001/014311 WO2002046144A1 (en) | 2000-12-07 | 2001-12-06 | Tetralone derivatives as antitumor agents |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20032531L true NO20032531L (no) | 2003-06-04 |
NO20032531D0 NO20032531D0 (no) | 2003-06-04 |
Family
ID=8170594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20032531A NO20032531D0 (no) | 2000-12-07 | 2003-06-04 | Tetralon-derivater som antitumormidler |
Country Status (26)
Country | Link |
---|---|
US (1) | US6531472B2 (no) |
EP (1) | EP1349830A1 (no) |
JP (1) | JP4091431B2 (no) |
KR (1) | KR20030077551A (no) |
CN (1) | CN100340545C (no) |
AR (1) | AR035659A1 (no) |
AU (2) | AU1607402A (no) |
BG (1) | BG107889A (no) |
BR (1) | BR0115988A (no) |
CA (1) | CA2430355A1 (no) |
CZ (1) | CZ20031833A3 (no) |
EC (1) | ECSP034642A (no) |
HK (1) | HK1060875A1 (no) |
HR (1) | HRP20030451A2 (no) |
HU (1) | HUP0400579A2 (no) |
IL (1) | IL156133A0 (no) |
MA (1) | MA26972A1 (no) |
MX (1) | MXPA03004947A (no) |
NO (1) | NO20032531D0 (no) |
NZ (1) | NZ526051A (no) |
PL (1) | PL365324A1 (no) |
RU (1) | RU2288220C2 (no) |
SK (1) | SK8512003A3 (no) |
WO (1) | WO2002046144A1 (no) |
YU (1) | YU45803A (no) |
ZA (1) | ZA200304262B (no) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6822267B1 (en) * | 1997-08-20 | 2004-11-23 | Advantest Corporation | Signal transmission circuit, CMOS semiconductor device, and circuit board |
US6706686B2 (en) * | 2001-09-27 | 2004-03-16 | The Regents Of The University Of Colorado | Inhibition of histone deacetylase as a treatment for cardiac hypertrophy |
ATE517624T1 (de) * | 2001-10-16 | 2011-08-15 | Sloan Kettering Inst Cancer | Behandlung von neurodegenerativen erkrankungen und krebs im gehirn |
US7148257B2 (en) | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
US7456219B2 (en) | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
BR0308250A (pt) | 2002-03-04 | 2005-01-11 | Aton Pharma Inc | Métodos de indução de diferenciação terminal |
AU2003226014A1 (en) * | 2002-03-28 | 2003-10-13 | Brigham And Women's Hospital, Inc. | Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease |
AU2003219555A1 (en) * | 2002-04-05 | 2003-10-20 | Fujisawa Pharmaceutical Co., Ltd. | Depsipeptide for therapy of kidney cancer |
EP1501489A4 (en) * | 2002-04-15 | 2007-11-21 | Sloan Kettering Inst Cancer | COMBINATION THERAPY FOR THE TREATMENT OF CANCER |
GB0217777D0 (en) * | 2002-07-31 | 2002-09-11 | Novartis Ag | Organic compounds |
US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US7250514B1 (en) | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
EP1570061A2 (en) * | 2002-12-05 | 2005-09-07 | Imperial College Innovations Limited | Control of apoptosis using a complex of an oligonucleotide and a regulatory peptide |
CA2518318A1 (en) | 2003-03-17 | 2004-09-30 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
JP4338734B2 (ja) | 2003-08-26 | 2009-10-07 | メルク エイチディーエーシー リサーチ エルエルシー | Hdac阻害剤による癌処置法 |
EP1667680A4 (en) | 2003-08-29 | 2008-10-08 | Aton Pharma Inc | COMBINED METHODS OF TREATING CANCER |
WO2005065681A1 (en) * | 2003-12-19 | 2005-07-21 | Takeda San Diego, Inc. | N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer |
WO2005066151A2 (en) * | 2003-12-19 | 2005-07-21 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
CA2561954A1 (en) * | 2004-04-05 | 2005-10-20 | Myogen, Inc. | Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure |
WO2005099747A1 (en) * | 2004-04-14 | 2005-10-27 | Medical Research Council | Selective killing of cancer cells by induction of acetyltransferase via tnf-alpha and il-6 |
KR100632800B1 (ko) | 2004-10-21 | 2006-10-16 | 한국화학연구원 | 히스톤 디아세틸라제 저해활성을 갖는 신규한하이드록시아마이드 유도체 및 이의 제조 방법 |
WO2006066133A2 (en) * | 2004-12-16 | 2006-06-22 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US7642253B2 (en) * | 2005-05-11 | 2010-01-05 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
TWI415603B (zh) | 2005-05-20 | 2013-11-21 | Merck Sharp & Dohme | 1,8-辛二醯基苯胺羥胺酸(suberoylanilide hydroxamic acid)之調配物及其製配方法 |
EA200800321A1 (ru) * | 2005-07-14 | 2008-06-30 | Такеда Сан Диего, Инк. | Ингибиторы гистондеацетилазы |
EP2275096A3 (en) | 2005-08-26 | 2011-07-13 | Braincells, Inc. | Neurogenesis via modulation of the muscarinic receptors |
EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
EP1976835A2 (en) * | 2006-01-13 | 2008-10-08 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
US9539303B2 (en) | 2006-04-24 | 2017-01-10 | Celgene Corporation | Treatment of Ras-expressing tumors |
JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | アンジオテンシン調節による神経新生 |
AU2007249435A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
KR20090064418A (ko) | 2006-09-08 | 2009-06-18 | 브레인셀즈 인코퍼레이션 | 4-아실아미노피리딘 유도체 포함 조합물 |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
EP3470536A1 (en) | 2013-10-01 | 2019-04-17 | The J. David Gladstone Institutes | Compositions, systems and methods for gene expression noise drug screening and uses thereof |
AU2014337102B2 (en) * | 2013-10-18 | 2019-02-28 | The General Hospital Corporation | Imaging histone deacetylases with a radiotracer using positron emission tomography |
EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
EP3461488A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dbait molecule and a hdac inhibitor for treating cancer |
US20220153687A1 (en) * | 2019-03-29 | 2022-05-19 | Taiwanj Pharmaceuticals Co., Ltd. | Peripheral alkyl and alkenyl chains extended benzene derivatives and pharmaceutical composition including the same |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2023041805A1 (en) | 2021-09-20 | 2023-03-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor |
WO2023194441A1 (en) | 2022-04-05 | 2023-10-12 | Istituto Nazionale Tumori Irccs - Fondazione G. Pascale | Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4448730A (en) * | 1981-03-24 | 1984-05-15 | Riet Bartholomeus Van T | Hydroxybenzohydroxamic acids, benzamides and esters and related compounds as ribonucleotide reductase inhibitors |
JPS61176523A (ja) * | 1985-01-30 | 1986-08-08 | Teruhiko Beppu | 制癌剤 |
US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
US5637946A (en) * | 1993-10-28 | 1997-06-10 | Lockheed Corporation | Thermally energized electrical power source |
AUPO721997A0 (en) | 1997-06-06 | 1997-07-03 | Queensland Institute Of Medical Research, The | Anticancer compounds |
-
2001
- 2001-11-27 AR ARP010105504A patent/AR035659A1/es not_active Application Discontinuation
- 2001-12-04 US US10/006,173 patent/US6531472B2/en not_active Expired - Fee Related
- 2001-12-06 CN CNB018197345A patent/CN100340545C/zh not_active Expired - Fee Related
- 2001-12-06 KR KR10-2003-7007640A patent/KR20030077551A/ko not_active Application Discontinuation
- 2001-12-06 NZ NZ526051A patent/NZ526051A/xx unknown
- 2001-12-06 WO PCT/EP2001/014311 patent/WO2002046144A1/en active IP Right Grant
- 2001-12-06 BR BR0115988-7A patent/BR0115988A/pt not_active IP Right Cessation
- 2001-12-06 RU RU2003119658/04A patent/RU2288220C2/ru active
- 2001-12-06 CA CA002430355A patent/CA2430355A1/en not_active Abandoned
- 2001-12-06 YU YU45803A patent/YU45803A/sh unknown
- 2001-12-06 AU AU1607402A patent/AU1607402A/xx active Pending
- 2001-12-06 JP JP2002547883A patent/JP4091431B2/ja not_active Expired - Fee Related
- 2001-12-06 AU AU2002216074A patent/AU2002216074C1/en not_active Ceased
- 2001-12-06 IL IL15613301A patent/IL156133A0/xx unknown
- 2001-12-06 MX MXPA03004947A patent/MXPA03004947A/es active IP Right Grant
- 2001-12-06 CZ CZ20031833A patent/CZ20031833A3/cs unknown
- 2001-12-06 HU HU0400579A patent/HUP0400579A2/hu unknown
- 2001-12-06 PL PL01365324A patent/PL365324A1/xx not_active Application Discontinuation
- 2001-12-06 SK SK851-2003A patent/SK8512003A3/sk unknown
- 2001-12-06 EP EP01999552A patent/EP1349830A1/en not_active Withdrawn
-
2003
- 2003-05-30 ZA ZA200304262A patent/ZA200304262B/en unknown
- 2003-06-04 MA MA27193A patent/MA26972A1/fr unknown
- 2003-06-04 HR HR20030451A patent/HRP20030451A2/hr not_active Application Discontinuation
- 2003-06-04 NO NO20032531A patent/NO20032531D0/no not_active Application Discontinuation
- 2003-06-05 EC EC2003004642A patent/ECSP034642A/es unknown
- 2003-06-06 BG BG107889A patent/BG107889A/bg unknown
-
2004
- 2004-06-01 HK HK04103910A patent/HK1060875A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ECSP034642A (es) | 2003-07-25 |
CZ20031833A3 (cs) | 2004-02-18 |
CA2430355A1 (en) | 2002-06-13 |
CN100340545C (zh) | 2007-10-03 |
CN1478072A (zh) | 2004-02-25 |
WO2002046144A1 (en) | 2002-06-13 |
IL156133A0 (en) | 2003-12-23 |
HK1060875A1 (en) | 2004-08-27 |
HUP0400579A2 (hu) | 2004-06-28 |
AR035659A1 (es) | 2004-06-23 |
JP4091431B2 (ja) | 2008-05-28 |
NZ526051A (en) | 2004-12-24 |
AU1607402A (en) | 2002-06-18 |
HRP20030451A2 (en) | 2005-04-30 |
JP2004515488A (ja) | 2004-05-27 |
MXPA03004947A (es) | 2003-09-10 |
AU2002216074B2 (en) | 2006-01-05 |
EP1349830A1 (en) | 2003-10-08 |
NO20032531D0 (no) | 2003-06-04 |
RU2288220C2 (ru) | 2006-11-27 |
BG107889A (bg) | 2004-06-30 |
SK8512003A3 (en) | 2004-04-06 |
PL365324A1 (en) | 2004-12-27 |
AU2002216074C1 (en) | 2006-12-07 |
US20020065282A1 (en) | 2002-05-30 |
ZA200304262B (en) | 2004-08-30 |
US6531472B2 (en) | 2003-03-11 |
BR0115988A (pt) | 2004-01-13 |
KR20030077551A (ko) | 2003-10-01 |
MA26972A1 (fr) | 2004-12-20 |
YU45803A (sh) | 2006-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20032531L (no) | Tetralon-derivater som antitumormidler | |
RU95108387A (ru) | Дикетопиперазин, способ его получения, фармацевтическая композиция, применение дикетопиперазина | |
DE60304059D1 (de) | 3-(2-hydroxy-phenyl)-1h-pyrazol-4-carbonsäureamid derivate als hsp90 inhibitoren zur behandlung von krebs | |
HUP0301932A2 (hu) | IL-1béta és TNF-a inhibitor benzofenon származékok, ezeket tartalmazó gyógyszerkészítmények és ezek alkalmazása gyógyszerkészítmények elżállítására | |
NO973198L (no) | Aryl- og heteroarylpurinforbindelser | |
MY131297A (en) | Herbicides | |
ES8607287A1 (es) | Un procedimiento para preparar derivados de 1,8-naftiridina | |
YU20199A (sh) | Heterociklični sukcinimidi i njihova primena kao metaloproteinaznih inhibitora | |
GB1457385A (en) | Substituted formamidines process for their preparation and their use as uv stabilisers | |
JOP20190239A1 (ar) | مركبات مثبطة لـ vmat2 وتركيبات منها | |
NO20044633L (no) | Nye alkoksypyridinderivater | |
DK534381A (da) | Fremgangsmaade til fremstilling af 2-oxoazetidinderivater | |
DK0656001T3 (da) | Nye 2-substituerede indan-2-mercaptoacetylamid-tricycliske derivater til anvendelse som enkefalinasehæmmere | |
ES8206462A1 (es) | Un metodo para preparar derivados de 2-oxoazetidina. | |
HUP0003455A2 (hu) | Benzoxazin- és benzotiazinszármazékok és gyógyszerekben történő alkalmazásuk | |
GB1428226A (en) | Process for the prepataion of aromatic hydroxylamines in the presence of catalysts | |
GB1458753A (en) | Process for the preparation of aromatic hydroxylamines by hydro genation of aromatic nitro derivatives | |
ES419661A1 (es) | Un procedimiento de preparacion de hidrazonas. | |
GB1054655A (no) | ||
NO20023513L (no) | Anvendelse av et ekstraheringsmiddel som et antiskummiddel ved fremstilling av vannfri maursyre | |
GB1437228A (en) | Lactones of the diazaxanthene series and dye precursors for copying processes | |
Angelino et al. | The use of immobilized enzymes in organic synthesis. Part 8. Oxidation of 1‐aryl‐3‐carbamoylpyridinium chlorides by rabbit liver aldehyde oxidase and bovine milk xanthine oxidase | |
Zygmunt | Inhibition of antibiotic formation by bromthymol blue and other indicators in Streptomyces rimosus | |
HUP0000080A2 (hu) | Metallopeptidáz inhibitor hatású foszfonsav-származékok, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
NO955071L (no) | abeo-Ergolin-derivater som 5HT1A-ligander |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |